None
No disclosed counterparties: CRS.
| Stage | CRS | % of rev | NUE | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $798M | 100.00% | $10.4B | 100.00% | NUE ×13.03 |
| Gross profit | $256M | 32.11% | $2.0B | 19.56% | CRS +12.5pp |
| Operating income | $196M | 24.61% | $1.6B | 15.67% | CRS +8.9pp |
| Pre-tax income | $192M | 24.10% | $1.6B | 15.63% | CRS +8.5pp |
| Net income | $163M | 20.36% | $1.3B | 12.31% | CRS +8.0pp |
| Stage | CRS | NUE | Gap · A − B |
|---|---|---|---|
| Revenue | $798M100.00% | $10.4B100.00% | NUE ×13.03 |
| Gross profit | 32.11%$256M | 19.56%$2.0B | CRS +12.5pp |
| Operating income | 24.61%$196M | 15.67%$1.6B | CRS +8.9pp |
| Pre-tax income | 24.10%$192M | 15.63%$1.6B | CRS +8.5pp |
| Net income | 20.36%$163M | 12.31%$1.3B | CRS +8.0pp |